Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Common Equity (2016 - 2025)

Fennec Pharmaceuticals' Common Equity history spans 15 years, with the latest figure at $35.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 704.09% year-over-year to $35.5 million, compared with a TTM value of $35.5 million through Dec 2025, up 704.09%, and an annual FY2025 reading of $35.5 million, up 704.09% over the prior year.
  • Common Equity for Q4 2025 was $35.5 million at Fennec Pharmaceuticals, up from -$4.5 million in the prior quarter.
  • The five-year high for Common Equity was $35.5 million in Q4 2025, with the low at -$11.6 million in Q4 2023.
  • Average Common Equity over 5 years is $3.0 million, with a median of -$2.6 million recorded in 2022.
  • Year-over-year, Common Equity crashed 475.84% in 2023 and then skyrocketed 704.09% in 2025.
  • Tracing FENC's Common Equity over 5 years: stood at $19.0 million in 2021, then tumbled by 113.51% to -$2.6 million in 2022, then plummeted by 352.39% to -$11.6 million in 2023, then soared by 49.48% to -$5.9 million in 2024, then skyrocketed by 704.09% to $35.5 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Common Equity are $35.5 million (Q4 2025), -$4.5 million (Q3 2025), and -$7.5 million (Q2 2025).